(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25219 A2

(51) International Patent Classification[7]: C07D 241/04, A61K 31/496, A61P 25/22

(21) International Application Number: PCT/EP00/09722

(22) International Filing Date: 5 October 2000 (05.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9923748.9 7 October 1999 (07.10.1999) GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALVARO, Giuseppe** [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **DI FABIO, Romano** [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **GIOVANNINI, Riccardo** [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **GUERCIO, Giuseppe** [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **ST-DENIS, Yves** [CA/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **URSINI, Antonella** [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agent: **FILLER, Wendy, Anne**; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(I)

(57) Abstract: The present invention relates to piperazine derivatives of formula (I) wherein R represents a halogen atom or a C_{1-4} alkyl group; R_1 represents hydrogen or a C_{1-4} alkyl group; R_2 represents hydrogen, a C_{1-4} alkyl, C_{2-6} alkenyl or a C_{3-7} cycloalkyl group; or R_1 and R_2 together with nitrogen and carbon atom to which they are attached respectively represent a 5-6 membered heterocyclic group; R_3 represents a trifluoromethyl, a C_{1-4} alkyl, a C_{1-4} alkoxy, a trifluoromethoxy or a halogen group; R_4 represents hydrogen, a $(CH_2)qR_7$ or a $(CH_2)rCO(CH_2)pR_7$ group; R_5 represents hydrogen, a C_{1-4} alkyl or a COR_6 group; R_6 represents hydrogen, hydroxy, amino, methylamino, dimethylamino a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen or a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms; R_7 represents hydrogen, hydroxy or NR_8R_9 wherein R_8 and R_9 represent independently hydrogen or C_{1-4} alkyl optionally substituted by hydroxy, or by amino; R_{10} represents hydrogen, a C_{1-4} alkyl I group or R_{10} together with R_2 represents a C_{3-7} cycloalkyl group; m is zero or an integer from 1 to 3; n is zero or an integer from 1 to 3; both p and r are independently zero or an integer from 1 to 4; q is an integer from 1 to 4; provided that, when R_1 and R_2 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group, i) m is 1 or 2; ii) when m is 1, R is not fluorine and iii) when m is 2, the two substituents R are not both fluorine,and pharmaceutically acceptable salts and solvates thereof.

WO 01/25219 A2